A 371,698-person database found no extra retina signal from GLP-1 medicines

Starting a GLP-1 receptor agonist carried no greater chance of vision-threatening retinopathy than starting a DPP-4 inhibitor or a sulfonylurea, in a retrospective analysis of 371,698 insured adults with type 2 diabetes and no retinopathy history. The pattern held at both shorter and longer durations of use.

Absolute numbers were small everywhere. Treatment for vision-threatening retinopathy reached 0.4% at two years and 1% at five for the GLP-1 group, 0.5% and 1.2% for sulfonylureas, and 0.3% and 0.7% for SGLT2 inhibitors, which reduced the relative risk 21% to 39% against the other classes.

What put the question on the table was a 2016 cardiovascular outcomes trial reporting retinopathy complications 76% higher on one GLP-1 medicine, and that molecule's label still carries the warning. Claims data is not a randomized answer, and the researchers never separated the people whose glycated hemoglobin fell steeply, which is the mechanism work from 1998 and 1985 implicates.

A dedicated trial on exactly this question is due to finish in 2027. Until it reads out, the decision belongs with a qualified clinician who knows a person's health history.

Read the full story at Medscape en Español ↗

Retatrutide is investigational and is not FDA-approved. Other medicines referenced here are covered as third-party news for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.